AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the issuance of key claims in...
Clinical trials of TAC01-CD19 expected to begin in third quarter 2019 AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)– Triumvira Immunologics, Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel...
AUSTIN, Texas & HAMILTON, Ontario & TORONTO – Triumvira Immunologics Inc. (Triumvira), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, has simultaneously submitted an IND to the U.S. Food...
AUSTIN, TX, and HAMILTON, ON, March 13, 2019 – Triumvira Immunologics, Inc., (Triumvira) a privately held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the appointment of Cynthia Molina as Vice...
Dr. Paul Lammers President & Chief Executive Officer Triumvira Immunologics www.triumvira.com Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – March 4, 2019 CEOCFO: Dr. Lammers, you have been president and CEO for a little...
MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative...
